Navigation Links
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Date:4/14/2008

Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts

DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613).

Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster highlights data indicating that S-110 showed robust anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Importantly, reduced toxicity was observed along with an increased half-life compared to decitabine.

"S-110's increased half-life, reduced toxicity and improvement of efficacy when compared to decitabine in its currently marketed formulations make it an attractive, next-generation hypomethylator for the treatment of hematoligic malignancies," said Dr. James Manuso, SuperGen's President and CEO. "As we develop S-110 further, we will continue to explore its potential to enhance solid tumors' sensitivity to standard chemotherapy agents, including cisplatin. We look forward to advancing this promising candidate to clinical trials later this year or early next year."

Copies of the 2008 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site http://www.superg
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
6. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.C. , Jan. 23, 2015 For the pharmaceutical ... in dealing with payers. Likewise, the importance of the managed ... will only continue to grow as payer formularies and provider ... therapies. At the same time, managed markets leaders ...
(Date:1/23/2015)... Jan. 23, 2015 A lot of discussion in the ... treating  certain illnesses, injuries, or conditions. As medical science advances, ... methods with ones that they consider to be more cutting ... not one textbook method of treatment that stands out as ...
(Date:1/23/2015)... Jan. 23, 2015  A new analysis of Centers for ... enrollment data shows that 81 percent of seniors chose ... extra discounts at certain pharmacies. The findings were released ... plans are now the foundation of Medicare Part D," ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... Primates Containing 1,000-Times the Dosage Recommended for Humans Shows ... Potential for Weekly or Bi-Monthly Dosing Frequency -NES-ZIONA, Israel, ... today reported results from a pilot toxicity study in ... long-acting human growth hormone (hGH), as well as to ...
... scientists, findings in ataxia telangiectasia-like disease and ... links between brain disease and cancer vulnerability ... 14 Scientists at St. ... the biological details distinguishing two related neurological ...
Cached Medicine Technology:Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP 2Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP 3Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP 4Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... have identified a key molecule Interleukin-12 (IL-12),that may provide ... food allergy the immune system responds to a food ... produces immunoglobulin E (IgE) antibodies, which normally help the ... can suffer life-threatening reactions, including anaphylactic shock. ...
... study conducted by the charity RNID suggests that 90 per cent ... damage-dullness of hearing or ringing in the ears-after a night ... half of whom visited a bar where they had to shout ... ,While a quarter of the study subjects reported ...
... that Paris Hiltons lie about abstaining from drugs has ... 23-day jail sentence, recently told Larry King during her ... all. ,However, multiple sources have confirmed the ... News. ,Hiltons pot smoking was a standard ...
... (OA) and rheumatoid arthritis (RA) face different treatment options ... . Two new studies examined patients decisions regarding therapy ... most RA patients are reluctant to change their treatment ... there are discrepancies in clinical trial results for glucosamine. ...
... -- A blood component called cystatin C, used to test ... for,those at risk of developing a condition known as ... has shown. ,Pre-diabetes is diagnosed when the amount ... above normal, an indication that glucose is not being absorbed ...
... resistance to food allergy has been identified and offers a ... treat food allergy and the only way for sufferers to ... sure they have injectable adrenaline at hand. ,Scientists ... Research in Norwich have found that a molecule called Interleukin-12 ...
Cached Medicine News:Health News:Alternative Treatments for Arthritis 2Health News:Alternative Treatments for Arthritis 3Health News:Early Indicator of Kidney Disease May Also Predict Risk of Pre-Diabetes 2Health News:Potential Target for Allergy Therapy 2
... pre-analytical process is receiving increased interest from ... Laboratory Automation (TLA) used to be the ... attractive for certain laboratories. In the last ... A concept based on pre-analytical, analytical and ...
... Laboratory Automation Network seamlessly combines two ... an automated sample processor, Accelspin centrifuge ... a single, powerful workstation. This modular ... that need a space- and cost-efficient ...
... award winning practically new Dade DAC II automatic ... automatic cell washer. The Dade (Baxter) Dac II ... primarily used to process samples for immunohematolgy tests. ... bench-top multipurpose instrument , Performs cell washing and ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
Medicine Products: